Merck Sharp + Dohme Corp.

Northwestern University

Acumen Pharmaceuticals, Inc.

Merck + Co., Inc.

Paul J Shughrue

Zhiqiang An

William Strohl

Andrew J Bett

Gene G Kinney

William L Klein

Mary P Lambert

Xiaoping Liang

Lei Chang

Paul Acton

Elizabeth Chen Dodson

Robert Breese

Weirong Wang

Alexander McCampbell

Wei-Qin Zhao

Fubao Wang

Renee C Gaspar

Ningyan Zhang

Kirsten L Viola

William F Goure

Min Xu

Abigail L Wolfe

Mary J Savage

Kristen Viola

Alexander Mccampbell

Nigyan Zhang

Franz F Hefti

This invention is a method and kit for treating a disease associated with, or resulting from, the accumulation of soluble oligomer amyloid beta 1-42 using an antibody, or antibody fragment thereof, that has a higher affinity for amyloid beta 1-42 oligomers than for amyloid beta 1-42 monomer, amyloid beta 1-40 monomer, plaques and amyloid beta fibrils and, optionally, a tau therapeutic or an inhibitor of amyloid beta production or aggregation.

Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42

The present invention relates to antibodies that bind amyloid &#x3b2;-derived diffusible ligands, also known as ADDLs. The antibodies of the invention are selective for ADDLs, can penetrate the brain, and are useful in methods of detecting ADDLs and diagnosing Alzheimer's disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with ADDLs.

Anti-ADDL monoclonal antibody and uses thereof

This invention is a selective A&#x3b2; oligomer kit and immunoassay method capable of reliably and sensitively detecting A&#x3b2; oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-A&#x3b2; oligomer antibodies, as capture and detection antibodies, to detect and quantify A&#x3b2; oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease.

Antibodies, kit and method for detecting amyloid beta oligomers

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A&#x3b2;-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid &#x3b2; 1-42.

Anti-ADDL antibodies and uses thereof

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A&#x3b2;-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid &#x3b2; 1-42.

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A&#x3b2;-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tauphosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid &#x3b2; 1-42.

Anti-addl antibodies and uses thereof

The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A&#x3b2;-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid &#x3b2;1-42.

Growing community of inventors

West Chester, PA, United States of America

Paul J Shughrue